T cell immunoreceptor with Ig and ITIM domains receptor (TIGIT)

The T cell immunoreceptor with Ig and ITIM domains receptor (TIGIT) is an immunomodulatory cell-surface receptor belonging to the immunoglobulin superfamily. It is primarily expressed on T cells and natural killer (NK) cells. TIGIT negatively regulates immune responses by binding ligands such as CD112 and CD155 expressed on antigen-presenting cells and tumor cells, leading to inhibition of T cell activation and function. In the context of cancer, TIGIT is targeted to overcome tumor-induced immune suppression. Vibostolimab is a humanized IgG1 monoclonal antibody directed against TIGIT; it blocks the TIGIT–ligand interaction, thereby preventing the immunosuppressive effects and reactivating anti-tumor immune responses[2][5][7]. Clinical development programs, including the KEYVIBE program, are broadly investigating the safety and efficacy of vibostolimab (alone and in combination with pembrolizumab, an anti-PD-1 antibody) in solid tumors such as non-small cell lung cancer, melanoma, and renal cell carcinoma. Combination regimens are designed to enhance immune attack on tumors, especially in cases resistant or refractory to PD-1/PD-L1-only blockade[1][2][3][5].

Other names

TIGIT receptorT cell immunoreceptor with immunoglobulin and ITIM domainVstm3

Immune checkpoint inhibition: Blockade of TIGIT receptor prevents TIGIT from binding its ligands (CD112 and CD155), restoring antitumor T cell activity by activating T lymphocytes to destroy tumor cells[2][3][5][7]. Combination immune modulation: Frequently combined with PD-1 blockade (e.g., pembrolizumab) to achieve a synergistic effect, as dual inhibition of TIGIT and PD-1 checkpoints enhances anti-tumor CD8+ T cell responses[2][4][5].